Exécution de notre outil de synthèse sur un nouvel article
Vérifiez l’article ci-dessous, puis lancez sa synthèse.
CAR T cell cancer immunotherapy: who does the job?
Dennis Christoph Harrer (University Hospital Regensburg, Leibniz Institute for Immunotherapy), Markus Barden (Leibniz Institute for Immunotherapy, University of Regensburg), Hinrich Abken (Leibniz Institute for Immunotherapy, University of Regensburg)
Résumé : Chimeric antigen receptor (CAR) T cells are capable to eliminate cancer cells in the treatment of hematologic malignancies, yet the efficacy is frequently inconsistent and limited by cancer cell resistance and antigen-loss resulting in early tumor relapses. While CAR T cells are deemed to be the primary effectors in controlling the tumor, maturing evidence indicates that therapeutic outcomes are shaped by a broader immune cell network involving both the endogenous adaptive and innate immunity. In this review, we reframe CAR T cell therapy as the induction of a multi-system immune response rather than a uni-directional cytotoxic cell-autonomous intervention. We discuss the respective contributions of CAR T cells, innate immune cells, and host adaptive immunity in controlling tumor progression and outline strategies to recruit innate immunity using TRUCKs, armored CAR T cells, as well as immunological adjuvants to surmount current limitations. Finally, we address the risks associated with excessive innate immune activation and propose that a calibrated, broad immune cell activation should be viewed as design principle for next-generation CAR T cell therapies.